Are we prepared to deal with the Alzheimer's disease pandemic

J. L. Holtzman

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


The recent publication of the results of the tarenflurbil trial in which a promising ?-secretase inhibitor failed to show efficacy in treating the sporadic form of Alzheimers disease represents yet another setback in our efforts to develop disease-modifying agents for the treatment of this dreaded condition.1 Unfortunately, this is just the latest in a line of promising agents that have failed to show any benefit when tested in well-designed clinical trials. Given that those reaching the age of 85 years have a 50% chance of developing this condition, such failures present not only a societal challenge but a very disturbing prospect for each of us. Furthermore, with the graying of the worlds population, the sporadic form of Alzheimers disease is becoming a major burden on our already limited health-care resources. It is estimated that today there are 45 million individuals in the United States with this disease and a total of 100 million worldwide. By the year 2050, these numbers are projected to increase to 14 million in the United States and 280 million worldwide.

Original languageEnglish (US)
Pages (from-to)563-565
Number of pages3
JournalClinical pharmacology and therapeutics
Issue number4
StatePublished - Oct 1 2010


Dive into the research topics of 'Are we prepared to deal with the Alzheimer's disease pandemic'. Together they form a unique fingerprint.

Cite this